SCCM
AZN icon

Schafer Cullen Capital Management’s AstraZeneca AZN Stock Holding History

Schafer Cullen Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-184,278
Closed -$18.4M – 222
2019
Q4 		$18.4M Sell
184,278
-158,859
-46% -$15M 0.22% 76
2019
Q3 		$30.6M Sell
343,137
-181,475
-35% -$15.7M 0.37% 69
2019
Q2 		$42.2M Buy
524,612
+5,188
+1% +$407K 0.5% 63
2019
Q1 		$42M Sell
519,424
-121,675
-19% -$9.59M 0.62% 57
2018
Q4 		$48.7M Sell
641,099
-134,082
-17% -$10.5M 0.75% 50
2018
Q3 		$61.3M Sell
775,181
-1,342,099
-63% -$102M 0.8% 55
2018
Q2 		$149M Sell
2,117,280
-114,243
-5% -$8.22M 1.92% 12
2018
Q1 		$156M Buy
2,231,523
+41,885
+2% +$2.9M 1.88% 10
2017
Q4 		$152M Sell
2,189,638
-25,436
-1% -$1.72M 1.77% 14
2017
Q3 		$150M Buy
2,215,074
+108,942
+5% +$6.88M 1.81% 15
2017
Q2 		$144M Buy
2,106,132
+5,001
+0.2% +$327K 1.79% 14
2017
Q1 		$131M Buy
2,101,131
+277,426
+15% +$16.1M 1.68% 22
2016
Q4 		$99.6M Sell
1,823,705
-293,721
-14% -$16.7M 1.35% 33
2016
Q3 		$139M Sell
2,117,426
-42,067
-2% -$2.75M 1.67% 21
2016
Q2 		$130M Sell
2,159,493
-17,279
-0.8% -$1M 1.58% 26
2016
Q1 		$123M Buy
2,176,772
+60,062
+3% +$3.61M 1.5% 28
2015
Q4 		$144M Sell
2,116,710
-39,329
-2% -$2.58M 1.71% 20
2015
Q3 		$137M Buy
2,156,039
+104,115
+5% +$6.85M 1.57% 24
2015
Q2 		$131M Sell
2,051,924
-47,828
-2% -$3.27M 1.35% 31
2015
Q1 		$144M Buy
2,099,752
+400,460
+24% +$27.8M 1.42% 30
2014
Q4 		$120M Sell
1,699,292
-597,671
-26% -$42.8M 1.51% 29
2014
Q3 		$164M Sell
2,296,963
-96,675
-4% -$7.08M 1.57% 24
2014
Q2 		$178M Sell
2,393,638
-1,392,175
-37% -$101M 1.64% 21
2014
Q1 		$246M Sell
3,785,813
-25,547
-0.7% -$1.65M 2.38% 3
2013
Q4 		$226M Buy
3,811,360
+14,205
+0.4% +$772K 2.24% 6
2013
Q3 		$197M Buy
3,797,155
+83,239
+2% +$4.18M 2.17% 9
2013
Q2 		$176M Buy
+3,713,916
New +$189M 2.1% 13

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schafer Cullen Capital Management's AZN Position: Q1 2020 in Review

Schafer Cullen Capital Management sold out of AstraZeneca (AZN) in Q1 2020, closing a stake of 184,278 shares — an estimated $18.4M sold.

Schafer Cullen Capital Management first reported a position in AZN in Q2 2013 and held it in 27 quarters. The position peaked at $246M in Q1 2014. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

  • Schafer Cullen Capital Management reported no remaining AstraZeneca position as of Q1 2020 after selling out during the quarter.
  • Schafer Cullen Capital Management sold 184,278 AstraZeneca shares in Q1 2020, an estimated $18.4M.
  • Schafer Cullen Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 27 quarters.
  • Schafer Cullen Capital Management's AstraZeneca position peaked at $246M in Q1 2014.
  • 603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on Schafer Cullen Capital Management's 13F filing for Q1 2020, filed 5 May 2020.